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Abstract | Observation is a conservative management option in infants with nonrefluxing hydronephrosis, 
primary nonrefluxing megaureter and ureterocele diagnosed postnatally following antenatal detection of 
hydronephrosis. Antibiotic prophylaxis might be a sensible regimen under these circumstances to prevent UTI 
in this population who are potentially at increased risk. However, studies examining the efficacy of prophylactic 
antibiotics are sparse in this setting. For each condition, prophylactic policies seem extremely variable, and 
UTI rates vary widely with comparable rates reported between patients followed on and off antibiotics. Overall, 
antibiotic prophylaxis seems unnecessary in patients with isolated low-grade hydronephrosis. Patients with 
high-grade nonrefluxing hydronephrosis seem at increased risk of UTI, with risk further increasing in patients 
with associated ureteral dilatation (hydroureteronephrosis) irrespective of the presence of a ureterocele. 
Obstruction might be an additional independent risk factor, but the diagnosis of obstruction is often 
possible only in retrospect. The data available suggest that infants are the most at risk of UTI during the first 
6 months of life, particularly if they undergo catheterization during workup examinations. Thus, antibiotic 
prophylaxis might be prudent during the first 6–12 months of life in patients with high-grade hydronephrosis 
and hydroureteronephrosis with or without ureterocele, and particularly before completion of the diagnostic 
workup. Paediatric urologists are urged to embark on controlled trials to compare patients followed with and 
without antibiotic prophylaxis.
Castagnetti, M. et al. Nat. Rev. Urol. advance online publication 8 May 2012; doi:10.1038/nrurol.2012.89
Introduction
Antenatal hydronephrosis—defined as a dilation of the 
foetal renal collecting system on prenatal ultrasono­
graphy (Figure 1)—is detected in approximately 1–5% 
of all pregnancies.1–4 Representing approximately 30% 
of all congenital defects detected on antenatal scans, 
hydronephrosis is the most common prenatally diag­
nosed anomaly.5,6 A variety of urological conditions can 
present with antenatal hydronephrosis, and a differential 
diagnosis can usually be made only after postnatal assess­
ment.7 The most common postnatal diagnoses include 
primary vesicoureteral reflux (VUR) in 10–20% of 
cases, nonrefluxing hydronephrosis (probably caused by 
uretero pelvic junction obstruction) in 10–30% of cases 
(Figure 2), nonrefluxing hydroureteronephrosis (also 
known as primary nonrefluxing megaureter [PNRM]) 
in 5–10% of cases (Figure 3) and ureterocele in 5% of 
cases (Figure 4).7 Unlike VUR, the last three conditions 
can be classified as primarily nonrefluxing dilatations 
and are the subject of this Review.
In the past 20 years, natural history series have shown 
that in many infants with nonrefluxing hydronephrosis 
and PNRM, the dilatation is only transient and tends 
to improve spontaneously over time without causing 
any clinical complications.8–12 Surgery is required only 
in patients with symptoms (mainly recurrent febrile 
UTI and flank pain), decreased differential renal func­
tion at presentation, worsening dilatation or differential 
renal function during follow­up, which equates to 20% 
of patients with nonrefluxing hydronephrosis and 10% 
of those with PNMR.8–12 Thus, observation has become 
an accepted management option, at least initially, for 
patients with these conditions. More recently, non­
operative management has also been proposed as an 
initial approach in selected patients with ureterocele.13
In principle, administration of antibiotic prophylactic 
drugs is a sensible measure for preventing UTI during 
observation in patients with a prenatally detected upper 
urinary tract dilatation whose condition has been con­
firmed postnatally.14 Antibiotic prophylaxis might be 
particularly appropriate in patients younger than 1 year 
of age as in this age group UTI are more difficult to diag­
nose, can develop quickly, can be particularly severe and 
are likely to cause renal injury and recur.14 Nevertheless, 
although several studies (including randomized clinical 
trials) have assessed the role of antibiotic prophylaxis in 
patients with primary VUR,15–17 very few studies have 
specifically focused on the role of antibiotic prophy­
laxis in patients with nonrefluxing upper urinary tract 
dilatation or uretero cele.18–22 Furthermore, the role of 
anti biotic prophylaxis in treating patients with primary 
VUR remains under scrutiny.15,16 Indeed, several meta­
analyses of recent trials showed the ineffectiveness of 
antibiotic prophylaxis in preventing UTI recurrence, and 
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concern mounts regarding its potential drawbacks.15–17 
For example, antibiotic prophylaxis might favour selec­
tion of antibiotic­resistant bacterial strains, is poorly 
accepted by parents and increases the health­care burden 
(Box 1).23,24
In this Review, we critically assess the available data 
on the role of antibiotic prophylaxis in the conservative 
manage ment of hydronephrosis, PNRM and ureterocele. 
For each condition, we assess the antibiotic prophylaxis 
Key points
 ■ Evidence supporting the use of antibiotic prophylaxis to prevent UTI in infants 
with nonrefluxing upper tract dilatations or ureterocele is inconclusive
 ■ Reported infection rates vary widely and are comparable in patients receiving 
prophylaxis and those who are not
 ■ The prescription of antibiotic prophylaxis for UTI seems to be influenced by the 
local medical standards, physician experience and the likelihood of prescribing 
postnatal investigations
 ■ Antibiotic prophylaxis can be avoided in patients with low-grade hydronephrosis 
and no ureteral dilatation
 ■ Patients with high grades of hydronephrosis are at increased risk of UTI; a 
dilated ureter increases the risk, whereas the presence of ureterocele does not
 ■ Infants are most at risk in the first 6 months of life, and catheterization 
performed during work-up might trigger the infection
policy reported in surveys of physician preferences, state­
ments of scientific societies and major natural history 
series. We also evaluate the results of controlled trials and 
uncontrolled series. Finally, we assess the time of onset 
of UTI and summarize the possible risk factors for UTI.
Antibiotic prophylactic regimens and UTI rates
Nonrefluxing hydronephrosis
General considerations
Assessing the role of antibiotic prophylaxis in non­
refluxing hydronephrosis presents two major issues. 
First, there is no consensus on the criteria, such as the 
degree of pelvic dilatation, to define a clinically sig­
nificant hydronephrosis.25,26 Second, there is no stand­
ard postnatal assessment protocol in patients with the 
condition. Indeed, currently there is no agreement on 
several aspects of postnatal assessment, including the 
need and timing for postnatal ultrasonography, voiding 
cysto urethrography (VCUG) and renal scintigraphy.25,26 
Many physicians tend either to perform ultrasono graphy 
(with or without renal nuclear scan) or to rely on pre natal 
results to plan postnatal treatment; many physicians 
also avoid invasive tests such as voiding cystourethro­
graphy.25,26 This approach is based on the assumption 
that, in the absence of ureteral dilatation, VUR occurs in 
fewer than 15% of patients and, when present, is usually 
low grade and tends to resolve spontaneously without 
causing UTI.27 Most studies consistently assess the risk 
of UTI and the need for antibiotic prophylactic treat­
ment in patients with hydronephrosis, irrespective of the 
presence of VUR.28,29 This choice is clinically meaningful, 
but impairs an accurate evaluation of the specific role of 
antibiotic prophylaxis in the individual conditions.
Recommended and reported practice
A 2004 survey of North American and European paedi­
atric urologists concerning the prescription of prophy­
lactic antibiotics for antenatal hydronephrosis revealed 
considerable variability in practice.26 The authors found 
that increased prophylactic antibiotic use paralleled the 
severity of the condition. Fewer than 5% of paediatric 
urologists recommended antibiotic prophylactics in 
patients with low­grade hydronephrosis (defined as an 
antero posterior diameter of the renal pelvis on the trans­
verse plane <4 mm or grade I hydronephrosis according 
to the Society for Fetal Urology [SFU] criteria).7 At the 
opposite end of the spectrum, more than 65% of urolo­
gists recommended antibiotic prophylaxis in severe 
cases (defined as an antero posterior diameter of the 
renal pelvis >10 mm or SFU grade IV hydro nephrosis). 
Furthermore, antibiotic use was considerably different 
between the two continents and seemed to be inversely 
correlated to the likelihood that the urologist would 
perform postnatal investigations. Specifically, paediat­
ric urologists from North America were less likely than 
European urologists to prescribe postnatal investiga­
tions and more likely to prescribe antibiotic prophy­
lactics. Notably, the choice to prescribe antibiotics also 
seemed to be influenced by the physician’s experience: 
46% of paediatric urologists in practice for >15 years 
Right pelvis
Left pelvis
Figure 1 | Antenatal ultrasonograph showing bilateral 
hydronephrosis.
Calyx
Calyx
Pelvis
Figure 2 | Postnatal ultrasonograph of hydronephrosis on 
the transverse plane. The infant has a dilated renal pelvis 
and calyces. The arrows point to the renal parenchyma.
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recommended antibiotic prophylaxis, whereas 68% of 
those in practice for <15 years recommended antibiotics 
(P <0.05). A different study noted no major differences in 
practice between paediatric urologists and nephrologists 
from the same cultural region (French­speaking coun­
tries) in managing ante natal hydronephrosis.25 Finally, a 
third study of US paediatricians found about half of those 
questioned prescribed antibiotic prophylactics for ante­
natal hydronephrosis.30 Of the paediatricians who did not 
prescribe antibiotics, about half referred the patient to a 
specialist immediately, leaving the latter to decide further 
management steps.30 Indeed, paediatricians without 
readily available specialist consultation were most likely 
to prescribe antibiotic prophylactics.30 Notably, even 
those US paediatricians who thought that the pub­
lished data on antibiotic prophylaxis were ambiguous 
and inconclusive still had threefold to sixfold greater 
odds of prescribing antibiotics than those declaring 
to have not read the published data.30
In their 2005 consensus statement on the evalua­
tion and management of antenatal hydronephrosis, the 
SFU recommend the use of antibiotic prophylactics in 
patients with high­grade hydronephrosis (SFU grade III 
or IV) or obstructive drainage patterns.7 However, the 
statement also emphasizes that no prospective ran dom­
ized trials are available to support the recommendations 
that compare antibiotic use against no antibiotics in 
children with these conditions; the efficacy of antibiotic 
prophylaxis has not been conclusively proven.
Of the major series on the natural history of con­
genital hydronephrosis and the trials comparing surgi­
cal intervention with observation, some do not define 
the use of antibiotic prophylactics in patients managed 
conservatively.31,32 By contrast, other studies have rec­
ommended the administration of antibiotics in the first 
year of life, or until there is significant improvement 
in hydronephrosis.8,9
Clinical studies
To the best of our knowledge, only one retrospective 
study has provided comparative data on the UTI rates in 
patients with pelviureteric junction obstruction receiving 
prophylactic antibiotics with those patients who are not. 
No difference was observed in the prevalence of UTI 
between patients who did and did not receive anti­
biotics;8 UTI occurred in five of 37 patients (14%) and 
a b
Bladder
Bladder
Figure 3 | Ultrasonograph of megaureter. a | Coronal plane view. b | Sagittal plane view. The arrows point to a dilated 
retrovesical ureter.
a
b
Bladder
UC
UP
LP
Figure 4 | Ultrasonograph showing a ureterocele.  
a | Ureterocele within the bladder. b | Ureterocele in a 
patient with upper pole hydroureteronephrosis. The arrows 
point to a dilated ureter. Abbreviations: LP, lower pole; UC, 
ureterocele; UP, upper pole.
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three of 16 (19%) patients, respectively. Unfortunately, 
the authors of this study did not disclose the prophy­
lactic regimen used or the characteristics of the patients 
receiving antibiotic prophylaxis. The latter in particular 
is an important limitation of the study because it remains 
unclear whether the administration of prophylaxis was 
reserved for patients with moderate degrees of dilatation, 
which might limit the validity of these results.
Several uncontrolled series assessed the risk of UTI in 
patients with antenatally detected nonrefluxing hydro­
nephrosis observed while either on or off antibiotic 
prophylaxis (Table 1). In patients not prescribed anti­
biotics, the prevalence of UTI ranged between 2% and 
31%. Only one series reported the outcomes of patients 
with antenatally detected hydronephrosis receiving pro­
phylactic antibiotics.21 In that study, the prevalence of 
UTI was 28%, comparable to the highest prevalence in 
the former series of patients not receiving antibiotics.
Primary nonrefluxing megaureter
General considerations
The postnatal management of PNRM is less contro versial 
than that of hydronephrosis. Indeed, if a dilated retro­
vesical ureter is seen on prenatal or postnatal ultrasono­
graphy of a patient with an antenatal hydronephrosis, the 
need for further investigation is generally agreed upon.33 
These investigations include VCUG to rule out VUR.
Recommended and reported practice
We are not aware of any surveys of physician preferences 
regarding the use of prophylactic antibiotics in the con­
servative management of patients with PNRM. As for 
hydronephrosis, the 2005 consensus statement of the 
SFU recommended the use of antibiotic prophylaxis in 
patients with PNRM.7
Of the major series on the natural history of PNRM 
reported in the past decade, some do not define the use 
of antibiotic prophylaxis in patients managed conserva­
tively,34 whereas others report inconsistent protocols. 
For example, McLellan et al.11 recommended prophy­
lactic antibiotics for their patients until the ages of 
9–12 months by physician preference, whereas Shukla 
et al.12 recommended antibiotic administration until the 
diagnosis was confirmed in all patients. Furthermore, 
Shukla et al.12 recommended prolonged antibiotic regi­
mens only in selected patients until the ureteral dilatation 
resolved or demonstrated a trend towards improvement. 
However, the characteristics of the subgroup receiving 
prolonged antibiotic prophylactics and the duration of 
the prolonged antibiotic prophylaxis were not reported.
Clinical studies
To the best of our knowledge, there are no controlled 
studies comparing antibiotic prophylaxis with no treat­
ment in patients with PNRM. The reported prevalence 
of UTI in series of patients with PNRM has a wide range, 
between 8% and 46% (Table 1), without any apparent 
reasons accounting for these differences. Coelho et al.21 
reported the only series of patients with antenatally 
detected PNRM receiving antibiotic prophylactics. In this 
series, the prevalence of UTI (25%) was similar to that 
in the series of patients who did not receive anti biotic 
prophylaxis (8–46%).
Ureterocele
General considerations
Ureterocele is a fairly variable clinical condition that can 
present with nonrefluxing hydroureteronephrosis of the 
ureter draining into the ureterocele, in either a single or 
duplex collecting system.35 However, ureterocele can also 
be associated with nonrefluxing hydroureteronephrosis 
or VUR in any of the ipsilateral or contralateral ureters 
as well as with bladder outlet obstruction (Figure 5).35 
Indeed, VUR in this context can be secondary to the 
bladder outlet obstruction or the distortion of the 
tri gonal anatomy caused by the ureterocele itself.
Postnatal assessment for ureterocele is not contro­
versial and most paediatric urologists agree on the need 
for a comprehensive assessment that includes ultrasono­
graphy, VCUG and renal nuclear scan.36 However, there 
is no consensus on the criteria for selecting patients for 
conservative management, which might be reasonable in 
patients without bladder outlet obstruction, good upper 
tract drainage on renal nuclear scan and absence of or 
low­grade­associated VUR (Table 2).13,37–40 On the basis of 
these criteria, only a minority (12–27% of all patients with 
ureterocele in published series) of patients would be eligi­
ble for conservative treatment.13,37,38 Regardless, the issue 
of whether these patients might benefit from antibiotic 
prophylaxis is also relevant to those who undergo surgery. 
Postponing early surgical intervention for a few months 
to await a comprehensive workup and allow the infant to 
grow is an approach that is increasingly used.41 Antibiotic 
prophylaxis might have an important role in this period 
between initial diagnosis and primary treatment.
Box 1 | Antibiotic exposure in early life
The use of antibiotics in infancy has been associated with drawbacks and 
complications, some of which are associated with chronic use during prophylactic 
treatment and some with short-term exposure. Adverse effects (such as 
nausea, vomiting and abdominal pain) are estimated to occur in 10.4% of infant 
patients on antibiotic prophylaxis for VUR, and are the reason for discontinuing 
treatment in 8.2% of these patients.50 A notable drawback of antibiotic use 
is the development of resistance, which is a global problem. One study found 
that children exposed to antibiotics for more than 4 weeks in a 6-month period 
were 23 times more likely to have an E. coli urinary isolate that was resistant to 
trimethoprim–sulphamethoxazole than children who had not received antibiotics.51 
Poor compliance is another relevant issue. One study found that only 17% of 
children on antibiotic prophylaxis for VUR actually had a urine sample positive for 
antibiotics.52 An analysis of over 35,000 patients with VUR noted that only 1 of 
10 was 100% compliant with antimicrobial prophylaxis.53 Patient noncompliance 
can favour the development of drug resistance and can result in breakthrough 
UTI as well as the increased need for hospital admission, additional physician 
visits, testing and extra medications—all of which result in increases in the cost 
of management.54,55 Finally, antibiotic exposure during the first year of life is 
associated with an increased risk of developing atopic diseases including eczema, 
wheeze, asthma and allergy later in life.56 The underlying mechanism has been 
summarized in the so-called hygiene hypothesis, which suggests that growing up 
in an increasingly hygienic environment with reduced microbial exposure might 
increase atopic (T-helper-2) immune responses and, therefore, the development of 
asthma and other allergic conditions.57
Abbreviation: VUR, vesicoureteral reflux.
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Recommended and reported practice
In a recent survey of paediatric urologists regarding the 
management of duplex­system ureterocele, some 85% of 
responders favoured prescribing antibiotic prophylaxis 
if observation was elected as the initial management 
strategy.36 This approach was still preferred by 71% of 
responders even if the patient had a negative VCUG.36 
This choice did not seem to be influenced by the region 
where the paediatric urologist was based or their 
experience (years of practice).
We are unaware of any guideline or recommendation 
from scientific or medical societies on the use of anti­
biotic prophylaxis specifically in patients with uretero­
cele. However, antibiotic prophylactics were consistently 
recommended in the series of patients with ureterocele 
managed conservatively,37–40 although the recommended 
regimens are quite variable, particularly with respect to 
the duration (Table 2).
Clinical studies
To the best of our knowledge, only one retrospec­
tive study has compared the infection rates in patients 
with ante natally detected ureteroceles treated with and 
without antibiotic prophylactics.42 In this small series, 
UTI occurred in 53% of patients overall, including 
three of seven (43%) patients who received prophylactic 
antibiotics and five of eight (62.5%) patients who did not.
The uncontrolled series of patients with ureterocele 
who did not receive antibiotic prophylactic treatment 
in the first year of life report high UTI rates. Two sepa­
rate Korean studies found UTI in seven of 10 (70%) 
patients with ureterocele18 and 10 of 17 (59%) patients.19 
In contrast with these data, UTI occurred in only four 
of 45 (9%) infants included in series of patients with 
ureteroceles given antibiotics (Table 2).13,37–40 However, 
these series had strict inclusion criteria and were uncon­
trolled; the patients included were possibly at low risk 
of developing UTI and would have fared well without 
antibiotic prophylaxis. Nevertheless, the reported UTI 
rates were also quite low in several series of unselected 
patients diagnosed antenatally who were prescribed anti­
biotic prophylactics while awaiting surgery.43–47 Under 
these circumstances, the rate of UTI ranged between 0% 
and 26% with a follow­up spanning between the first 
3 months and 6 months of age (Table 3).43–47 Another 
study found that the rate of UTI at 6 months of age in 
40 patients receiving antibiotic prophylaxis (unspecified 
regimen) was not statistically different to the rate in 32 
patients who underwent early endoscopic decompression 
of the ureterocele and subsequent antibiotic prophylaxis 
(unspecified regimen).48 Although the study was limited 
by an arbitrary allocation of patients to either treatment, 
it suggests that antibiotic prophylaxis alone might be as 
effective as surgical decompression in patients in the first 
6 months of age. Whether the UTI rates would be the 
same without antibiotic prophylaxis remains unclear.
Timing of UTI onset
Although no study reports the timing of UTI onset sep­
arately for each condition, all the series do report that 
UTI onset is very early irrespective of the condition. 
Song et al.18 reported the mean age at onset of UTI as 
2.6 months in infants with obstructive hydronephrosis, 
with UTI developing before 6 months of age in 93% of 
patients. Similarly, Lee et al.19 report that the first UTI 
occurred at an average age of 4.1 ± 2.7 months, and UTI 
developed before 6 months of age in 84% of patients. 
Finally, Roth et al.20 reported an average patient age at 
the occurrence of UTI of 6.1 months (with a range of 
1–11 months).
Notably, infection developed soon after a workup 
investigation that required catheterization in eight of 
the 83 patients who developed UTI in the series by Lee 
et al.19 and two of the four who developed UTI in the 
Table 1 | UTI in series of patients with nonrefluxing hydronephrosis or PNRM* 
Study n Inclusion criteria Prophylaxis regimen Follow-up Rate of UTI
Patients with 
hydronephrosis
Patients 
with PNRM
Song 
et al.18 
(2007)
93 Antenatal hydronephrosis‡; 
severe obstruction on 
diuretic renography; no 
circumcision
No prophylaxis 12 months after 
birth
23/75 (31%) 7/18 (39%)
Lee et al.19 
(2008)
412 Antenatal hydronephrosis§; 
no circumcision
No prophylaxis 12 months after 
birth
46/351 (13%) 28/61 
(46%)
Roth et al.20 
(2009)
92 Antenatal hydronephrosis‡ No prophylaxis 27 months after 
birth
1/56 (2%) 3/36 (8%)
Islek et al.22 
(2011)
84 Antenatal hydronephrosis§ No prophylaxis Median 18 
(12–24) months 
after diagnosis
0/84 (0%) NR
Coelho 
et al.21 
(2008)
61 Antenatal hydronephrosis§; 
no circumcision
50 mg cephalexin daily in 
the first 2 months of life, 
then 1–2 mg per kg of 
trimethoprim without any 
age limit for discontinuation
Median 
24 months after 
birth 
13/53 (28%) 2/8 (25%)
*Diagnosed postnatally following antenatal detection of a urinary tract dilatation and followed conservatively either with or without antibiotic prophylaxis. 
‡Society for Fetal Urology grade III or IV. §Any grade. Abbreviations: NR, not reported; PNRM, primary nonrefluxing megaureter. 
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series by Roth et al.20 Although excluding these patients 
did not change the overall timing of onset, this obser­
vation might deserve clinical consideration. If UTI is 
triggered by invasive procedures performed during the 
workup such as catheterization, antibiotic prophylaxis 
might be effective if administered in the period before 
completion of the diagnostic workup, or even during the 
single investigations requiring catheterization.
Risk factors for UTI
A number of factors might influence the risk of devel­
oping UTI in patients with hydronephrosis, PNRM and 
ureterocele, although few studies report these. Again, we 
could not identify studies assessing the risk factors for 
UTI in each condition separately.
In general, patient sex and circumcision status are the 
most obvious risk factors for UTI. However, in all but one 
study of patients with nonrefluxing upper urinary tract 
dilatation or ureterocele, sex was not associated with 
an increased risk of UTI.18–22 The only study reporting 
a correlation between female sex and UTI included in 
the multivariate analysis a significant number of patients 
with congenital hydronephrosis caused by primary 
VUR,21 which limits the validity of the study. Only one 
study assessed the influence of circumcision status on the 
development of UTI; no difference was reported in the 
UTI rate between circumcised and uncircumcised boys.20
Lee et al.19 investigated the risk of UTI in relation to the 
degree of hydronephrosis, and observed that high grades 
(SFU grade III and IV) of hydronephrosis were signifi­
cantly associated with an increased risk of UTI. UTI 
occurred in 4% of patients with grade I hydronephrosis 
compared with 40% of those with grade IV (P <0.001), 
which corresponded to an almost 17­fold increased 
risk.19 This variable was also significant on multivariate 
analysis.19 The counterpart of this observation is that low­
grade hydronephrosis is associated with a reduced risk of 
UTI. In line with this observation, a study of 223 patients 
(≤12 months of age) with an anteroposterior diameter 
of the renal pelvis on the transverse plane of 10–15 mm 
and 230 healthy controls without evidence of any urinary 
tract dilatation reported infection rates of 3.6% and 2.5%, 
respectively.29 In another study by the same authors, the 
UTI rate reached 7% in patients with severe hydro­
nephrosis (defined as an anteroposterior diameter of the 
renal pelvis on the transverse plane >15 mm).49
Lee et al.19 also reported that the presence of obstruc­
tive uropathy is an independent risk factor. However, the 
authors defined obstructive uropathy as an obstructive 
drainage pattern on dynamic scintigraphy, or a negative 
clinical course with worsening of the dilatation or renal 
function loss over subsequent follow­up renal nuclear 
scans. The latter implies that the diagnosis of obstruction 
in a few patients is possible only in retrospect consider­
ing multiple investigations, which is clinically unpracti­
cal for deciding whether or not to commence antibiotic 
prophylaxis at presentation.
Additional independent risk factors have also been 
identified. For example, the presence of a hydroureter 
in addition to high­grade hydronephrosis seems to be 
an independent risk factor for UTI.18,19 In patients with 
hydro ureteronephrosis the simultaneous presence of a 
ureterocele did not appear to be an independent risk 
factor for UTI.18,19 Thus, the presence of hydrouretero­
nephrosis is more important than the underlying 
condition for predicting the likelihood of UTI.
Conclusions
The few reports summarized in this Review reveal much 
variability in the policies concerning the administra­
tion of antibiotic prophylaxis in infants with congenital 
nonrefluxing hydronephrosis, PNRM and ureterocele. 
Unexpectedly, local medical standards and physician 
experience might influence the decision to prescribe 
antibiotics. Moreover, the likelihood that a patient is 
prescribed antibiotic prophylactics seems to be inversely 
correlated with the likelihood they undergo postnatal 
investigations. Furthermore, it seems that some physi­
cians, although aware that evidence regarding the role 
of antibiotic prophylaxis is inconclusive, still prefer to 
prescribe the treatment. Multiple factors might account 
for such a decision, including the preference to err on the 
side of caution or for medicolegal reasons.30
The risk of UTI seems to be low in patients with 
low­grade isolated hydronephrosis (namely no ure­
teral dilatation), SFU grade I or II hydronephrosis or 
an antero posterior diameter of the renal pelvis <15 mm. 
In these patients, the risk of developing a UTI does not 
differ from that of the general population and antibiotic 
prophylactics are not necessary.
However, risk of UTI seems to increase with increas­
ing severity of hydronephrosis. Increased urinary stasis in 
a severely dilated urinary system might account for this 
observation. Associated ureteral dilatation, namely pres­
ence of hydro ureteronephrosis, seems to further increase 
the risk of UTI, possibly because the extension of the 
severely dilated urinary reservoir to the bladder makes 
urinary contamination easier. Interestingly, the presence 
of ureterocele does not seem to be an independent risk 
factor, as the risk of UTI in patients with hydrouretero­
nephrosis and ureterocele is comparable to that in patients 
with hydro ureteronephrosis alone. An additional inde­
pendent risk factor for infections might be the presence of 
a cb
LP
Figure 5 | Voiding cystourethrograph showing a ureterocele. a | The ureterocele is a 
filling defect within the bladder during the filling phase. b | The ureterocele is 
encroaching on the posterior urethra during micturition. No vesicoureteral reflux is 
visible on these films. c | The ureterocele with associated ipsilateral LP vesicoureteral 
reflux. The arrows point to the ureterocele. Abbreviation: LP, lower pole.
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obstruction, although the definition of obstruction remains 
unclear because the presence of obstruction can sometimes 
only be diagnosed in retrospect based on the clinical course 
(such as the development of symptoms or a functional loss 
during follow­up). Patient sex and circumcision status do 
not appear to influence the rate or likelihood of UTI. In 
terms of timing of UTI onset, the first 6 months of life are 
the most risky period. Furthermore, workup procedures 
requiring catheterization might trigger infection.
Overall, the possible increased risk of UTI in patients 
with nonrefluxing upper urinary tract dilatation does not 
warrant the use of antibiotic prophylaxis. The evidence 
regarding the risk of UTI in patients treated with pro­
phylactic antibiotics and those left untreated are incon­
clusive. The range of reported infection rates is very 
wide, with overlap in the UTI rates of patients receiv­
ing prophylaxis and those not. Of the very few series 
available, at least one21 reported a very low UTI rate in 
patients left untreated, another study reported a rate of 
UTI in patients receiving treatment comparable to that 
of patients left untreated.18–20
In the absence of reliable, reproducible data, anti biotic 
prophylactics should always be prescribed to neonates 
and infants undergoing investigations that require cath­
eterization. Additionally, antibiotic prophylaxis might 
be prudent in patients with high­grade hydronephrosis 
(SFU grade III and IV), as well as in patients with hydro­
ureteronephrosis with or without ureterocele. Antibiotics 
might be most effective if given in the first 6–12 months 
of life, or until after completion of the baseline workup. 
Nevertheless, this Review emphasizes that the evidence 
supporting this practise is weak and inconclusive. 
Therefore, paediatric urologists should be aware of the 
limits of antibiotic prophylaxis for UTI in these patients, 
and are urged to embark on controlled trials to compare 
patients treated with antibiotics with those left untreated, 
and to compare different regimens.
Table 2 | Antibiotic prophylaxis in patients with ureterocele managed conservatively
Study n Inclusion criteria Antibiotic prophylaxis Follow-up (years) UTI rate (%)
Shankar 
et al.13 (2001)
14  
of 52
Asymptomatic; lower pole VUR; no lower 
pole nonrefluxing hydronephrosis; no 
BOO; upper pole function <10%
Until completion of 
toilet training or 
5 years of age in case 
of persisting VUR
Median, 8; range, 
1.6–12.8 
0
Merguerian 
et al.37 (2003)
10  
of 60
Minor upper pole dilatation; no evidence 
of obstruction on renal scan
NR Mean, 
4.95 ± 2.08‡
0
Coplen and 
Austin38 
(2004)
4  
of 34
Multicystic dysplasia in the ureterocele 
moiety; no ureteric dilatation; VUR in 
other moieties; no BOO
Until resolution of VUR 
or completion of toilet 
training
Mean, 3; range, 
1.2–4.5
25 (1 
patient)
Han et al.39 
(2005)
11* Good or no function in the ureterocele 
moiety; no evidence of high-grade 
obstruction on renal nuclear scan§ 
Until completion of 
toilet training
Median, 3.4; range 
1–8
27 (3 
patients)
Di Renna and 
Leonard40 
(2006)
6* Asymptomatic; lower pole VUR; no lower 
pole nonrefluxing hydronephrosis; no 
BOO; upper pole function <10% or >10% 
with no obstruction
For a mean of 
1.5 years (range 
2 months to 4 years)
Median, 5; range, 
1–11
0
*Total population size NR. ‡Range not reported. §Half-life <30 min. Abbreviations: BOO, bladder outlet obstruction; NR, not reported; VUR, vesicoureteral reflux.
Table 3 | UTI rates in patients with ureterocele treated with or without antibiotics before surgical decompression
Study n Prophylaxis Age at surgery (months) UTI rate (%)
Decter et al.43 
(2001)
27 25 mg amoxicillin daily from birth NR 0
Husmann et al.44 
(1995)
33 25 mg per kg birth weight amoxicillin or cefaclor daily 
from birth 
3 9 (3 patients)
Shekarriz et al.45 
(1999)
25 No uniform policy 3 12 (3 patients)*
Upadhyay et al.46 
(2002)
40 2 mg per kg birth weight trimethoprim or trimethoprim–
sulfamethoxazole daily from 6 weeks of age
6 12 (5 patients)
Chertin et al.47 
(2005)
35 Regimen NR 4 26 (9 patients)
*Two patients on and one patient off prophylaxis. Abbreviation: NR, not reported.
Review criteria
A MEDLINE/PubMed search was performed using the 
keywords “hydronephrosis”, “ureteropelvic junction 
obstruction”, “hydroureteronephrosis”, “megaureter”, and 
“ureterocele”. The search was limited to papers published 
in English between January 1, 1990 and February 29, 2012 
and to human studies in children aged 0–18 years. Only full-
text papers were considered. Selection of papers relevant 
to the topic of this Review was not aimed to be systematic, 
and inclusion of most recent literature was favoured. The 
reference lists of selected papers were also searched for 
additional relevant literature.
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